Welcome to let’s tALK, Takeda Oncology’s hub for ALK+ advanced non-small cell lung cancer (aNSCLC) educational meetings.

Here you can learn about upcoming ALK+ aNSCLC focused webinars, listen to previous webinar recordings, and find out information on our Expert on Demand webinar meetings. Click on the links below to discover more about each initiative currently available.

Content on this website includes information on ALUNBRIG▼(brigatinib). Any information provided on ALUNBRIG is within its licensed indication.

ALUNBRIG is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.¹

ALUNBRIG is indicated as monotherapy for the treatment of adult patients with ALK‑positive advanced NSCLC previously treated with crizotinib.¹